First-in-human data for the potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in the treatment of metastatic colorectal cancer to be featured in an oral presentation. Phase I data for tuvusertib, the lead asset from the company’s unique…
Several years ago, Melissa Martinez was watching her youngest daughter’s basketball game when a player had a seizure. With no one else knowing how to help, Martinez’s daughter shouted, “My mom’s a nurse! She can help!” Martinez quickly stepped in…
RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition, naming Upneeq® as “Best for Lift” in the professional category,…
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are often confused, as their names and symptoms—such as diarrhea and abdominal pain—are similar. However, these gastrointestinal (GI) disorders are fundamentally different and require distinct treatment approaches. Understanding the differences is…
A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami Beach, FL, from May 28-31, 2024. The company…
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer’s disease treatment. ACI-24.060 is an anti-Abeta active…
Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a BCM. This breakthrough underscores BCMs’ potential as a treatment avenue…
Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an exclusive worldwide licensing agreement for MZE001. This novel therapeutic candidate…
Sanofi, in its pursuit of a robust vaccine portfolio, has forged a co-exclusive licensing agreement with Novavax, a biotech firm headquartered in Maryland, USA. The terms of this agreement encompass several key elements: Sanofi gains a co-exclusive license to globally…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, reported today that the Phase 3 KEYNOTE-B21 trial assessing KEYTRUDA, Merck’s anti-PD-1 therapy, alongside chemotherapy as an adjuvant treatment, with or without radiotherapy, did not achieve…
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit research and development organization Medicines for Malaria Venture (MMV), has…
Soleo Health, a prominent provider of specialized pharmacy services for rare and ultra-rare diseases, has been designated as a limited distribution specialty pharmacy partner for dispensing RYPLAZIM® (plasminogen, human-tvmh), developed by Kedrion Biopharma. RYPLAZIM, the first and only FDA-approved treatment…